← All trials
NCT03699241
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 3, 2018
- Primary completion
- May 20, 2020
- Completion date
- May 20, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International AIDS Vaccine InitiativeLead sponsor
- GlaxoSmithKlineCollaborator
- University of WashingtonOverall official - principal investigator
- Harvard UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- Kenya AIDS Vaccine InitiativeCollaborator
- Kenya AIDS Vaccine InitiativeOverall official - principal investigator
- University of WashingtonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.